Retrospective analysis of low-dose methadone and QTc prolongation in chronic pain patients by Huh, Billy & Park, Chan-Hong
Korean J Anesthesiol 2010 Apr; 58(4): 338-343 
DOI: 10.4097/kjae.2010.58.4.338  Clinical Research Article
Copyright ⓒ Korean Society of Anesthesiologists, 2010 www.ekja.org
Background:  Methadone is a synthetic opioid that is widely used for the treatment of chronic pain. The association 
between methadone treatment and QT interval prolongation or which can lead to torsades de pointes has been 
confirmed with larger studies on high dose methadone.  The aim of this study was to determine the effect of 
methadone on the QTc interval in patients, whether the daily dose of methadone should be lower than what has been 
previously investigated.
Methods:  A total of 130 patients were included, with 90 patients in the methadone group and 40 patients in the 
control group.  For each ECG, heart rate, QT interval and corrected QT (QTc) interval were recorded.  The patient 
demographics, methadone dose and serum level, duration of methadone use and past medical history were collected.
Results:  The QTc interval was significantly longer in the treatment group than in the control group (443 ± 30.0 ms 
versus 408 ± 28.0 ms, respectively, P < 0.0001) and more patients in the treatment group had a QTc interval greater 
than 450 ms (36.7% versus 7.5%, respectively, P = 0.0005).  The QTc interval was not associated with methadone dose 
P = 0.9278), serum level (P = 0.2256) or duration of treatment (P = 0.1822).
Conclusions:  This study has shown that methadone use is associated with longer QTc intervals, even among patients 
with daily doses of less than 80 mg.  In this study, no correlation was found between QTc duration and methadone 
dose, serum levels or duration of use. However, the magnitude of the QTc interval was associated with female gender 
and the use of antidepressants.  (Korean J Anesthesiol 2010; 58: 338-343)
Key Words:  Methadone, Opioid, QT interval.
Retrospective analysis of low-dose methadone and QTc 
prolongation in chronic pain patients
Billy Huh
1, and Chan-Hong Park
2
1Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA, 
2Deaprtment of Anesthesiology and Pain 
Medicine, Daegu Wooridul Hospital, Daegu, Korea
Received: December 24, 2009.  Revised: January 8, 2010.  Accepted: February 1, 2010.
Corresponding author: Chan-Hong Park, M.D., Deaprtment of Anesthesiology and Pain Medicine,
 Daegu Wooridul Hospital, 3056-6, 
Daemyeong 4-dong, Nam-gu, Daegu 705-718, Korea. Tel: 82-53-212-3179, Fax: 82-53-212-3049, E-mail: magary6@yahoo.co.kr
    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
CC339 www.ekja.org
Korean J Anesthesiol Huh and Park
Introduction
    Methadone is a synthetic opioid that is widely used for 
the treatment of chronic pain and as a substitute for heroin 
addiction. Although it is generally considered safe [1], a recent 
series of case reports have suggested an association between 
methadone treatment and QT interval prolongation or Torsades 
de pointes [2-8]. This association has been confirmed with large 
studies [9-15] and a retrospective analysis of the FDA MedWatch 
program [16]. The patients in these studies have generally 
been on high dose methadone (>120 mg/day). However, 
QT interval prolongation has been noted with daily doses 
below 65mg [5,8,11] and no cutoff value for a safe dose has 
been identified. Although some studies have found a positive 
correlation between methadone dose and the magnitude of 
QTc prolongation, the association is usually stronger when 
additional factors such as gender, length of treatment and 
concomitant drug use are accounted for [9,11-13,15].
    The mechanism by which methadone increases the QT 
interval is blockade of the HERG potassium channel (also 
called “KCNH2”), which mediates cardiac repolarization 
[15,17]. Methadone undergoes hepatic metabolism by CYP3A4, 
whose serum concentration is increased in disease states with 
decreased hepatic function [18] or if drugs that interact with 
CYP3A4 are used simultaneously [19]. QT prolongation can 
also be caused by drugs that directly affect the HERG potassium 
channel, such as cocaine [20] and a variety of prescription 
drugs [19,21,22], or by hypokalemia [22]. In patients with these 
additional risk factors, QT prolongation can be seen even with 
low doses of methadone. 
    The aim of this study was to determine the effect of low dose 
methadone on the QTc interval in patients recruited from a 
chronic pain clinic, where the daily dose of methadone is lower 
than what has been previously investigated.
Materials and Methods
    Approval for this study was obtained from Institutional 
Review Board. Patients were identified by a retrospective review 
of the electronic medical records of adult patients at pain clinic. 
Patients were included if they received methadone for treatment 
of chronic pain and had both a 12-lead electrocardiography 
(ECG) and a serum methadone measurement recorded during 
the study period. A control group of patients had a recorded 
12-lead ECG, but had no past history of methadone use. 
Patients with a history of cardiac pathology (e.g. arrhythmia, 
heart block, etc) were excluded from the study. A total of 130 
patients were included, with 90 patients in the methadone 
group and 40 patients in the control group. For each ECG, the 
heart rate, QT interval and QTc interval were recorded. All 
measurements were generated by an automated ECG machine. 
A prolonged QTc interval was defined as greater than 450 ms. 
The following data were collected from each patient’s medical 
record: patient demographics (age, gender, height, and weight), 
methadone dose and serum level, duration of methadone use 
and past medical history. The use of the following medications 
was documented for each patient: analgesics, including 
narcotics, non-steroidal anti-inflammatory drug (NSAID) 
and antiepileptic drugs; antidepressants, including selective 
serotonin release inhibitor (SSRI), tricyclic antidepressants 
and selective norepinephrine release inhibitor, and benzodia-
zepines. Methadone serum levels were assumed to be steady-
state, as all patients were prescribed a stable dose of methadone 
every six hours. All data were collected without regard to the 
patients’ methadone treatment status.
    The associations between QTc interval and methadone use 
(dose, serum level and duration) and continuous demographic 
data (height, weight, body mass index) were assessed using 
Pearson and Spearman correlation coefficients. The difference 
in QTc interval between methadone users and non-users 
was tested by ANCOVA and the difference in the incidence of 
prolonged QT interval was tested by logistic regression. Both 
were adjusted for effects of gender and concomitant analgesic 
use. The interaction between gender and methadone use 
was also tested with Tukey adjustment for gender subgroup 
comparisons. Prior to data collection, we estimated that a 
sample size of 90 patients in the treatment group would have 
82% power to detect a Pearson correlation coefficient r = 30 
between methadone dose and QTc interval. In addition, a 
control group of 40 patients would have 90% power to detect a 
difference of 20 ms in mean QTc between the methadone and 
control groups, assuming that the common standard deviation 
of the QTc is 35 [10]. The level of significance for all statistical 
analyses was set at P < 0.05 (2-tailed tests). All statistical 
analyses were performed using SAS version 9.
Results
    The treatment and control groups were similar in terms of 
gender distribution, age, height and BMI (Table 1), though 
actual weight was higher in the control group (94.9 kg versus 
85.2 kg, respectively, P = 0.0349). The methadone dose in the 
treatment group ranged from 5-80 mg/day (median 30 mg/
day) and the methadone serum level ranged from 10-348 ng/
ml (median 81.5 ng/ml). The duration of methadone treatment 
ranged from 1-150 months (median 43 months).
    By unadjusted comparison, the QTc interval was significantly 
longer in the treatment group than in the control group (443 
± 30.0 ms versus 408 ± 28.0 ms, respectively, P < 0.0001) and 
more patients in the treatment group had a QTc interval greater 340 www.ekja.org
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than 450 ms (36.7% versus 7.5%, respectively). Four patients, 
all of whom were in the methadone group, had a QTc interval 
greater than 500 ms. In the methadone group, the QTc interval 
was not associated with methadone dose (P = 0.9278), serum 
level (P = 0.2256) or duration of treatment (P = 0.1822). The QTc 
interval was higher in females and shorter patients (P = 0.0061 
and 0.0072, respectively), as well as patients who were taking 
antidepressants (P = 0.0397). However, the effects of gender and 
height were linked because there was a significant association 
between female gender and shorter height (P < 0.0001). To 
avoid autocorrelation, only gender was used in subsequent 
regression analyses. No significant association was found 
between QTc and age (P = 0.5470) or BMI (P = 0.7398). 
    The difference in QTc interval between the two groups 
remained significant after adjusting for gender, the number 
of pain medications each patient was taking and the use of 
antidepressants (Table 2). The adjusted values for the treatment 
and control groups were 441.0 ms and 408.5 ms, respectively, 
with a mean difference of 32.5 ms (95% Confidence Intervals 
= 21, 44 ms). The methadone effect remained significant 
among gender subgroups, with average QTc values as follows: 
females on and off methadone 448 ± 27.4 ms and 417 ± 27.6 
ms, respectively, and males on and off methadone 436 ± 32.0 
ms and 397.4 ± 25.0 ms, respectively (P < 0.0001 for both). The 
interaction between methadone and gender was not significant 
(P = 0.97)(Fig. 1). The adjusted odds ratio for prolonged QTc 
interval (>450 ms) among methadone users was 7.2 (95% 
Confidence Intervals = 2.3, 31.8).
Discussion
    This study provides further evidence that methadone use is 
associated with prolonged QTc intervals, even at low doses (less 
than 80 mg/day). However, there was no association between 
the magnitude of the QTc interval and any of the quantitative 
methadone indices, including dose, serum level, and duration 
of use. The QTc interval was greater among females, shorter 
patients and those taking antidepressants. After adjusting for 
gender, the use of antidepressants and the number of pain 
medications each patient was taking, the estimated mean QTc 
interval was still 32.5 ms greater in the methadone group than 
in the control group (441.0 ms versus 408.5 ms, respectively). 
This effect was also seen in gender subgroup analysis, where 
QTc interval among methadone users was 30.5 ms and 38.1 
ms greater than the control group for females and males, 
respectively. No instances of torsades de pointes were reported 
and all patients with a prolonged QT interval were clinically 
asymptomatic.
    The upper limit of normal for QTc intervals has been incon-
sistently defined in the literature, with values ranging from 430 
to 470 ms. However, absolute QTc values greater than 500 ms 
or changes from baseline greater than 30 ms have consistently 
been predictive of the development of drug-induced torsades 
de pointes [23]. It is strength of this study that the absolute QTc 
Table 1.  Demographics and Electrocardiographic Characteristics
Methadone 







    Height (cm) 
    Weight ( kg)
Electrocardiographic data
    QTc duration (ms)
    prolonged QTc (>450 ms)
      51  ± 12.4
      51  ± 56.7
29.7  ± 7.5
168.7  ± 10.6
  85.2  ± 24.3
442.5  ± 29.9
      33  ± 36.7
     51  ± 11.1
     21  ± 52.5
32.2  ± 7.4
171.4  ± 9.9
 94.9  ± 22.7
407.9  ± 28.0
    3  ± 7.5
   0.9724
   0.7047
   0.0835
   0.1738
   0.0349*
<0.0001*
   0.0005*
Continuous data reported as mean ± SD.  Binomial data reported as 
number (%). *Significant P value.
Table 2. Medication Data
Methadone 





    Daily dose (mg/day)
    Serum level (ng/ml)
    Duration of use (months)
Concomitant analgesics
    Narcotics
    NSAIDs
    Antiepilepitcs
Antidepressants
    SSRIs
    TCAs
    Duloxetione
Benzodiazepines
  
  30 (5-80)
   81.5 (10-348)














  8 (20.0)
  6 (15.0)
  4 (10.0)
0 (0.0)
  6 (15.0)
   0.0608
<0.0001*
   0.2437
   0.0326*
   0.0061*
   0.1258
   0.7747
   0.0563
   0.0824
Methadone data reported as median (range).  Remaining data re-
ported as number of patients (% of patients).  SSRI:  selective sero-
tonin reuptake inhibitor. TCA:  tricyclic antidepressants. *Significant 
P < 0.05.
Fig. 1. Mean QTc and methadone treatment, by gender. The interac-
tion between methadone and gender was not significant (P = 0.97).341 www.ekja.org
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values are statistically different between the two groups, and 
that the results are not dependent on an arbitrary value that 
defines a prolonged QTc interval. All four patients who had 
absolute QTc values greater than 500 ms were in the methadone 
treatment group. However, no patient developed torsades de 
pointes, despite the increased risk for this complication. The 
adjusted QTc difference between the methadone and control 
groups was 32.5 ms, although this data alone is not sufficient 
to say that methadone caused an increase in the QTc interval 
because no baseline data was collected. However, given the 
similarity between the two groups in terms of demographics 
and concomitant medications, it is unlikely that the use of 
methadone did not contribute to these results.
    The interaction between methadone dose and QTc duration 
has been investigated in a number of previous studies, most 
of which have included patients receiving a higher dose of 
methadone than those included in this study. Maremmani et al. 
[24] studied 83 patients receiving a mean daily methadone dose 
of 87 mg (10-600 mg/day). They found that 83% of patients had 
QTc values greater than standardized values for age and sex. 
However, no correlation was found between QTc duration and 
methadone dose. In a study of 138 patients receiving median 
dose of 170.9 mg/day (40-290 mg/day) of methadone, Peles 
et al. [10] found only a weak trend toward prologation of QTc 
duration with methadone dose, which did not reach statistical 
significance (r = 0.13, P = 0.1). Correlation between QTc 
duration and methadone serum levels was not demonstrated (r 
< 0.01, P = 1). These results are similar to our study, which also 
showed no correlation between these measures.
    Some studies, however, have found a relationship between 
methadone dose and QTc duration. Ehret et al. [11] studied 
EKGs among 247 hospitalized patients, 167 of whom were 
receiving methadone (4-600 mg/day, median 100 mg/day). 
A weak, though statistically significant, correlation was found 
between methadone dose and QTc interval (r = 0.2, P < 0.01). 
Furthermore, QTc intervals of greater than 500 ms occurred 
with doses as low as 30 mg/day and among the six patients who 
developed torsades de pointes the average dose ranged from 
40 to 200 mg/day. Similarly, our study contained four patients 
with QTc intervals greater than 500 ms who were receiving 
20-40 mg/day of methadone. These findings highlight the 
difficulty in defining a safe range of methadone, as significant 
QTc prolongation can occur even at very low doses. Cruciani et 
al. [9] studied 140 patients receiving a median dose of 110 mg/
day (20-1,200 mg/day) of methadone. They found that QTc 
was associated with an interaction between dose and duration. 
They found a dose x duration interaction (d = 0.86, P = 0.0009), 
which was significant only for males who had been receiving 
treatment for less than 12 months.
    Martell et al. [12,13] have documented a change in QTc 
interval using baseline and follow-up EKGs after beginning 
methadone. In the first study, Martell et al. [13] analyzed EKGs 
from 132 patients at baseline and 2 months after beginning 
methadone therapy with doses from 30-150 mg/day. Over 
this period, the QTc increased by 10.8 ms (P < 0.0001) with 
greater changes among males and those receiving greater than 
110 mg/day of methadone. In a follow-up study, Martell et al. 
[12] studied 160 patients at baseline and 6 and 12 months after 
starting therapy. The median methadone doses were 80 mg/day 
(20-180 mg/day) and 90 mg/day (20-200 mg/day) at 6 and 
12 months, respectively. They found a significant correlation 
between methadone dose and the magnitude of QTc interval 
increase at 6 months (r = 0.18, P = 0.03), though the significance 
of this effect was marginal at 12 months (P = 0.08). However, 
the magnitude of QTc increase at 12 months was significantly 
associated with methadone serum trough (r = 0.37, P = 0.008) 
and peak levels (r = 0.32, P = 0.03). The average QTc change 
from baseline to 6 and 12 months was 12.4 ms (P < 0.001) and 
10.7 ms (P = 0.001), respectively, both of which fall below the 
cut-off of 30 ms that defines the risk for torsades de pointes. 
Two patients had a QTc greater than 500 ms at each time point, 
but no patients developed torsades de pointes. 
    These studies have provided conflicting conclusions about 
the relationship between methadone dose and the QTc interval. 
Some have used a case-control design, while others collect data 
prospectively and analyze the impact of methadone use over 
time. Although either design provides valuable information, it 
is difficult to compare these studies. In addition, the range of 
methadone doses has varied considerably among these studies. 
It is possible that a correlation exists between methadone dose 
and QTc duration, but that studies such as ours, which include 
a very small range of doses, do not contain a large enough range 
of data for this correlation to become statistically significant. 
These studies have also differed with regards to the duration 
of methadone treatment. The results found by several authors 
[9,10,12,13] were dependent on the duration of methadone 
treatment and did not reach significance after 12 months. Peles 
et al. [10] hypothesized that the initial increase in QTc interval 
on starting methadone therapy may be an adaptation that does 
not continue linearly over time. Indeed, among the initial case 
reports of patients who presented with torsades de pointes, 
many patients had either recently initiated or increased their 
methadone dose [4-6]. The median duration of methadone 
therapy in our study was 43 months. Therefore, it is possible that 
no correlation was found between the duration of methadone 
treatment and the length of the QTc interval because of the 
length of time over which the patients in the study had been 
taking methadone.
    In each study, methadone use has been associated with longer 
QTc intervals. However, in most cases, additional factors have 342 www.ekja.org
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been important in determining the length of the QTc interval. 
Ehret et al. [11] found that in addition to methadone dose, 
QTc prolongation was associated with hypokalemia, hepatic 
dysfunction and comedication with CYP3A4 inhibitors. In 
fact, when the other factors were considered synergistically, 
they were stronger predictors of QTc interval duration than the 
methadone dose. A model using all four of these predictors 
accounted for 31.8% of the QTc variability, indicating that other 
important factors had not been included. Although Peles et al. 
[10] did not find a significant correlation between methadone 
dose and QTc duration in their overall sample, a significant 
correlation was found among patients who tested positive for 
cocaine (r = 0.4, P = 0.003), which is known to block the HERG 
potassium channel that contributes to cardiac repolarization 
[19-22]. Krantz et al. [5] reported 17 patients who had developed 
torsades de pointes while receiving very high dose methadone 
(mean 397 mg/day). Among these patients, 14 had other 
potential risk factors for arrhythmia, including hypokalemia, the 
use of other drugs that interfered with methadone metabolism 
or directly prolonged the QT interval and structural heart 
disease. Similarly, in our study, the methadone indices were not 
correlated with the QTc interval. The only factors which were 
correlated with QTc interval were demographic variables and 
comedications.
    The main limitation of this study is the lack of baseline patient 
data. Although the QTc measurements were significantly 
different between the two groups, we cannot say that metha-
done was associated with a change in QTc interval in the 
treatment group. Therefore, a follow-up study of QTc duration 
among low-dose methadone users at baseline and 6 and 12 
months after beginning treatment will be conducted to deter-
mine the change in QTc duration in this patient population. 
In addition, some authors have noted that the QTc interval 
decreases after patients decrease their methadone intake 
[2,4,7,11]. This would be incredibly important among patients 
who have QTc intervals greater than 500 ms and are at greater 
risk for developing torsades de pointes. We will therefore collect 
follow-up data for patients in our clinic who decrease or stop 
their methadone to determine how the QTc interval responds to 
these changes.
    This study has shown that methadone use is associated with 
longer QTc intervals, even among patients with daily doses 
of less than 80 mg. We have confirmed the findings of other 
studies, which have shown that the QTc interval is prolonged 
over a wide range of methadone doses and that no safe dose, 
below which QTc prolongation does not occur, has been found 
at this time. Although four patients in this study had QTc 
intervals greater than 500 ms, it is important to note that none 
had torsades de pointes or other adverse events due to their 
prolonged QTc duration. In this study, no correlation was found 
between QTc duration and methadone dose, serum levels or 
duration of use. However, the magnitude of the QTc interval was 
associated with female gender and the use of antidepressants.
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